Jarushka Naidoo: Stage III ALK+ NSCLC – consolidation ALK TKI vs Durvalumab vs Observation

Jarushka Naidoo shared on X:

“Stage III ALK+ NSCLC: consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab versus Observation:

-67 patients, ALKi=15 Durva=30 obs=22

-mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001)

Small n, but useful.”

Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer|Journal of Toracic Oncology

Authors: Amin H. Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib, Justin M. Cheung, Jessica J. Lin, Yufei Liu, Steven H. Lin, Kaushal Parikh, Arthi Sridhar, Purnima Shakya, Thomas J. Dilling, David Kaldas, Jhanelle E. Gray, Anastasiya Lobachov, Jair Bar, Heike Luders, Christian Grohe, Shruti Gupta, Ticiana Leal, Bailey Fitzgerald,  Fionnuala Crowley, Yu Fujiwara, Thomas U. Marron, Molly Wilgucki, Joshua Reuss, Luxi Chen, Kamya Sankar, Jacqueline V. Aredo, Joel W. Neal, Heather A. Wakelee, Rohit Thummalapalli, Helena Yu,  Ryan Whitaker, Ana Velazquez, Meera Ragavan, Alessio Cortellini, David J. Kwiatkowski, Abdul Rafeh Naqash, Sarah B. Goldberg, So Yeon Kim

Source: Jarushka Naidoo/X

More posts featuring Jarushka Naidoo on oncodaily.com

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.